Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3-7], chronic lymphocytic leukemia [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12-15].

Source: Biology of Blood and Marrow Transplantation - November 27, 2019 Category: Hematology Authors: Ying Wang, Kunming Qi, Hai Cheng, Jiang Cao, Ming Shi, Jianlin Qiao, Zhiling Yan, Guangjun Jing, Bin Pan, Wei Sang, Depeng Li, Xiangmin Wang, Chunling Fu, Feng Zhu, Junnian Zheng, Zhenyu Li, Kailin Xu Source Type: research